Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Regeneron Pharmaceuticals (REGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 33,355,406
  • Shares Outstanding, K 109,276
  • Annual Sales, $ 6,711 M
  • Annual Income, $ 2,444 M
  • 60-Month Beta 1.13
  • Price/Sales 5.01
  • Price/Cash Flow 13.84
  • Price/Book 3.56

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate 4.60
  • Number of Estimates 1
  • High Estimate 4.60
  • Low Estimate 4.60
  • Prior Year 4.70
  • Growth Rate Est. (year over year) -2.13%

Price Performance

See More
Period Period Low Period High Performance
1-Month
295.27 +5.32%
on 06/05/19
321.49 -3.27%
on 05/22/19
+6.04 (+1.98%)
since 05/17/19
3-Month
295.27 +5.32%
on 06/05/19
415.89 -25.23%
on 04/02/19
-103.49 (-24.97%)
since 03/15/19
52-Week
295.27 +5.32%
on 06/05/19
442.00 -29.64%
on 03/04/19
-4.32 (-1.37%)
since 06/15/18

Most Recent Stories

More News
Regeneron (REGN) Presents Positive Data on Lymphoma Candidate

Regeneron (REGN) reports positive early-stage data on REGN1979 in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma.

CELG : 97.30 (+0.82%)
ALNY : 71.50 (+2.10%)
REGN : 310.98 (+1.88%)
SNY : 42.65 (+0.42%)
Regeneron Pharm Has Returned 24.3% Since SmarTrend Recommendation (REGN)

SmarTrend identified a Downtrend for Regeneron Pharm (NASDAQ:REGN) on March 8th, 2019 at $403.54. In approximately 3 months, Regeneron Pharm has returned 24.25% as of today's recent price of $305.67.

REGN : 310.98 (+1.88%)
Regeneron CD20xCD3 Bispecific REGN1979 Shows Positive Results in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma, including in CAR-T Failures

93% overall response (13 of 14 patients) and 71% complete response rates (10 of 14 patients) in follicular lymphoma grades 1 to 3a treated with REGN1979 5 mg to 320 mg

REGN : 310.98 (+1.88%)
SmarTrend Watching for Potential Rebound in Shares of Regeneron Pharm After 1.06% Loss

Regeneron Pharm (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $302.92 to a high of $307.42. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of...

REGN : 310.98 (+1.88%)
2019 Update: Ophthalmic Drugs Market Global Statistics and Forecast Till 2028

MarketResearch.Biz provide a 10-year forecast for the Ophthalmic Drugs market between 2019 and 2028. The study serves key trends that are presently impressing the growth of the Ophthalmic Drugs market....

VRX.TO : 30.80 (-3.33%)
SNPHF : 15.1500 (+2.02%)
AGN : 115.73 (-0.16%)
NVS : 89.76 (+0.27%)
SHPG : 179.20 (+4.10%)
TEVA : 8.20 (-0.49%)
REGN : 310.98 (+1.88%)
26.0% Return Seen to Date on SmarTrend Regeneron Pharm Call (REGN)

SmarTrend identified a Downtrend for Regeneron Pharm (NASDAQ:REGN) on March 8th, 2019 at $403.55. In approximately 3 months, Regeneron Pharm has returned 25.97% as of today's recent price of $298.73.

REGN : 310.98 (+1.88%)
Alnylam Completes Rolling NDA Submission to FDA for Givosiran

Alnylam (ALNY) completes the rolling NDA submission to the FDA for givosiran, which is being evaluated for the treatment of acute hepatic porphyria.

MDCO : 35.82 (+1.53%)
ALNY : 71.50 (+2.10%)
NVS : 89.76 (+0.27%)
REGN : 310.98 (+1.88%)
Why Is Regeneron (REGN) Down 8.8% Since Last Earnings Report?

Regeneron (REGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

REGN : 310.98 (+1.88%)
Glaxo's Nucala Gets CHMP Nod for 2 Self-Administered Options

GlaxoSmithKline (GSK) announces that the EMA???s Committee for Medicinal Products for Human Use has issued a positive opinion for two self-administered options of its asthma drug, Nucala.

AZN : 39.98 (+0.78%)
REGN : 310.98 (+1.88%)
GSK : 39.93 (-0.47%)
SNY : 42.65 (+0.42%)
Ophthalmology Market, 2025 - Major Players are Novartis, Bausch & Lomb, F.Hoffman La-Roche, Regeneron Pharmaceuticals, & Allergan

The "Global Ophthalmology Market by Segment, by Disease, by Drug Class, by Region - Market Outlook 2025" report has been added to ResearchAndMarkets.com's offering.

AGN : 115.73 (-0.16%)
REGN : 310.98 (+1.88%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade REGN with:

Business Summary

Regeneron Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic medicines for the treatment of serious medical conditions. Regeneron has therapeutic candidates for the potential treatment of obesity, rheumatoid arthritis, cancer, and asthma...

See More

Key Turning Points

2nd Resistance Point 319.71
1st Resistance Point 315.35
Last Price 310.98
1st Support Level 304.19
2nd Support Level 297.39

See More

52-Week High 442.00
Fibonacci 61.8% 385.95
Fibonacci 50% 368.64
Fibonacci 38.2% 351.32
Last Price 310.98
52-Week Low 295.27

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar